Advancing Multiple mRNA Clinical Studies to Treat and Prevent Disease

Across our internally developed and partnered mRNA programs, we are simultaneously advancing mRNA development candidates for many diseases into and through clinical studies. Our Early Development Engine enables this with a combination of internal and external capabilities around process development, conduct of Good Laboratory Practice (GLP) (IND-enabling) toxicology studies, global regulatory interactions and clinical study preparation and execution. The Early Development Engine is structured to deliver many high quality mRNA drugs to human proof of concept (PoC) data.

Our Approach to Early mRNA Drug Development

Our early development process is designed to deliver the highest quality mRNA medicines from development candidate (DC) nomination to human proof-of-concept (PoC) data. This is how we approach the process.

Early Development Engine Components

Learn about the components of our integrated Early Development Engine, including our clinical development manufacturing site in Norwood, MA.

Download facts and figures on our new Norwood manufacturing site.